Nitto Denko Corp. engages in the manufacture and sale of adhesives, optical films, semiconductors, electronic devices, and consumer products. It operates through the following segments: Industrial Tape, Optronics, Human Life, and Others. The Industrial Tape segment deals with the manufacture and sale of sealing, protective, process, and automotive materials. The Optronics segment offers optical films, printed circuits, and high-precision substrates. The Human Life segment handles the manufacturing services for nucleic acids, nucleic acid synthesis materials, and medical-related materials. The Others segment includes new businesses. The company was founded on October 25, 1918 and is headquartered in Osaka, Japan.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Manufactures electrical insulation materials and appliances

Part of GSK Plc, Beecham Group Plc is a British company located in Middlesex. The firm functions as an investment holding company. It was founded in 1928.\nThe company says this about itself: The principal activity Of the Company is the holding of Intercompany bans and receipt Of interest. The Company had previously been an investment holding company. The Company is a member Of the GlaxoSmithKline Group (the 'Group\"). The directors do not envisage any change to the nature of the business in the future,

Develops products for the treatment of human immune systems disorders and diseases

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

Tokyo Metropolitan Institute of Medical Science is a Japanese private company. The firm operates as a research institute that develops medicine.

Hubei Huaguan Zhongke Bio-Pharmaceutical Co., Ltd., established on 2004-02-23, Business scope includes biopharmaceutical research and development;Cosmetic sales;Nutrition and Health Consulting Services;Realtor.(Projects with special national regulations can only be operated after approval or with a valid license);Bangbaoli Cow Colostrum Nutritional Powder,Three categories of medical devices6840Clinical laboratory analysis instruments and diagnostic reagents,one type6864Production and sales of medical hygiene materials and medical dressings;Medical Device II,Three types of sales;other food(Healthy food)Sales;production of disinfectants(Used at the same time as the sanitation license approval document when selling)And anti(suppress)Bacteria.(Operating period,Scope of business and period approved by the license,consistent range)

They have provided general information for the allergy sufferer and healthcare professionals about the prevention, diagnosis and treatment of the allergic condition with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy), the only treatment to deal with the underlying cause and not just the symptoms!

Kewpie Corp. engages in the manufacture and sale of food products. It operates through the following business segments: Condiment and Seasoning, Salad and Delicatessen, Egg, Fruit Solutions, Fine Chemicals, Distribution, and Common. The Condiment and Seasoning segment manufactures and sells mayonnaise, dressings, vinegar, pasta sauce, baby food, and nursing food products. The Salad and Delicatessen segment provides salads and side dishes. The Egg segment offers egg products such as liquid egg, frozen egg, soft boiled egg, omelets, egg salad, and processed egg. The Fruit Solutions segment supplies processed fruit products to dairy and food manufacturers such as jams, peanut cream, and terrine spread. The Fine Chemicals segment provides hyaluronic acid as an ingredient for pharmaceuticals, food, and cosmetics. The Distribution segment deals with food transportation and storage services. The Common segment includes the sale of food and manufacturing machinery. The company was founded by Toichiro Nakashima on November 30, 1919 and is headquartered in Tokyo, Japan.

Oji produces and sell pulp and a variety of paper products The company organizes itself into four segments based on product type.They have newspaper business, paper business and pulp manufacturing related businesses.

Toray Industries, Inc. (東レ株式会社 Tōre Kabushiki-gaisha) is a multinational corporation headquartered in Japan that specializes in industrial products centered on technologies in organic synthetic chemistry, polymer chemistry, and biochemistry.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of biopharmaceutical products. It focuses on providing treatment for allergic rhinitis and asthma caused by dust mites. It offers dust mite drops, and dust mite skin prick diagnosis kits. The company was founded by Geng Xi Hu on September 19, 2002 and is headquartered in Huzhou, China.

Jiangsu Huaguan Biotechnology Co., Ltd., established on 2009-03-06, Business scope includes biological products,medical instruments,In vitro diagnostic reagent development;Production,sales category,Class II medical device,Three categories6840In vitro diagnostic reagents;Sales of Class III Medical Devices:6840Clinical Laboratory Analytical Instruments,6864Medical hygiene materials and dressings,6866Medical polymer materials and products,In vitro diagnostic reagents(Equipment),disinfectant;Healthy food(new start immune capsules,Green Multidimensional Capsules),beverage production,Health food wholesale.Production of hygiene products and single-use medical products;Disinfectant production;Wholesale hygiene products;Daily necessities retail;General merchandise sales;Cosmetics Wholesale;Cosmetics Retail(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments);Prepackaged food sales,Import and export business of various commodities and technologies.(Not including those prohibited by the state or restricted by enterprises) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Non-residential real estate leases(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)